Abstract
Ocrelizumab (OCZ) has been approved in 2018 in Italy for the treatment of patients with multiple sclerosis (MS), but real-world data about its use are limited. Aims: To evaluate effectiveness and safety of OCZ for primary progressive MS (PPMS), active secondary progressive (SPMS) and relapsing remitting MS (RRMS) patients recruited at the MS Center of Bari, Italy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
